Paraoxonase 1 Gene Polymorphisms Do Not Influence the Response to Treatment in Alzheimer's Disease

被引：11

作者：

Klimkowicz-Mrowiec, A. ^{[1
]}

Marona, M. ^{[3
]}

Spisak, K. ^{[3
]}

Jagiella, J. ^{[3
]}

Wolkow, P. ^{[2
]}

Szczudlik, A. ^{[1
]}

Slowik, A. ^{[1
]}

机构：

[1] Jagiellonian Univ, Dept Neurol, PL-31503 Krakow, Poland

[2] Jagiellonian Univ, Dept Pharmacol, PL-31503 Krakow, Poland

[3] Univ Hosp, Dept Neurol, Krakow, Poland

来源：

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS | 2011年 / 32卷 / 01期

关键词：

Acetylcholinesterase inhibitors; Alzheimer's disease; Paraoxonases; Polymorphisms; Response to treatment; DONEPEZIL; ACETYLCHOLINESTERASE;

D O I：

10.1159/000330343

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Background: Acetylcholinesterase inhibitors (AChEIs) are the treatment of choice for patients with Alzheimer's disease (AD). However, their efficacy is moderate and differs from patient to patient. Recent studies suggest that the Q192R variant of the paraoxonase 1 gene (PON1) might affect individual susceptibility to these drugs. Methods: We investigated the influence of 3 single nucleotide polymorphisms (SNPs) in PON1 (rs 662, rs 854560, rs 705381) and the APOE common polymorphism in 101 Polish patients with late-onset AD in response to treatment with AChEIs. Results: No significant differences were observed between carriers and non-carriers of the PON1 SNPs or the APOE common polymorphism in terms of treatment response. These results did not change after stratification of APOE status. Conclusion: Our results suggest that both the investigated PON1 and APOE common SNPs do not influence treatment response to AChEIs in patients with AD. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：26 / 31

页数：6

共 50 条

[1] Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease
Dantoine, TF
Drouet, M
Debord, J
Merle, L
Cogne, M
Charmes, JP
[J]. ALZHEIMER'S DISEASE: VASCULAR ETIOLOGY AND PATHOLOGY, 2002, 977 : 239 - 244
[2] Paraoxonase 1 gene polymorphisms in Alzheimer disease and vascular dementia
Cagnin, A
Lunardelli, V
Moretti, R
Briani, C
Gabelli, C
Terrazzino, S
Miccichè, F
Stecca, A
Passarotto, M
Ricchieri, GL
Pizzolato, G
Leon, A
Battistin, L
[J]. NEUROBIOLOGY OF AGING, 2006, 27 : S2 - S2
[3] Genetic association of paraoxonase 1 polymorphisms with Alzheimer's disease
Cagnin, A.
Zambon, A.
Lunardelli, V.
Zarantonello, G.
Leon, A.
Battistin, L.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 283 (1-2) : 255 - 255
[4] Gene polymorphisms of interleukin-1α influence the course of Alzheimer's disease
Kölsch, H
Ptok, U
Bagli, M
Papassotiropoulos, A
Schmitz, S
Barkow, K
Kockler, M
Rao, ML
Maier, W
Heun, R
[J]. ANNALS OF NEUROLOGY, 2001, 49 (06) : 818 - 819
[5] Association analysis of the paraoxonase-1 gene with Alzheimer's disease
Cellini, Elena
Tedde, Andrea
Bagnoli, Silvia
Nacmias, Benedetta
Piacentini, Silvia
Bessi, Valentina
Bracco, Laura
Sorbi, Sandro
[J]. NEUROSCIENCE LETTERS, 2006, 408 (03) : 199 - 202
[6] Association study of the paraoxonase 1 gene with the risk of developing Alzheimer's disease
Chapuis, Julien
Boscher, Maud
Bensemain, Faiza
Cottel, Dominique
Amouyel, Philippe
Lambert, Jean-Charles
[J]. NEUROBIOLOGY OF AGING, 2009, 30 (01) : 152 - 156
[7] MDR1 GENE POLYMORPHISMS IN ALZHEIMER'S DISEASE
Feher, A.
Juhasz, A.
Pakaski, M.
Kalman, J.
Janka, Z.
[J]. EUROPEAN PSYCHIATRY, 2012, 27
[8] Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases
Wingo, Thomas S.
Rosen, Ami
Cutler, David J.
Lah, James J.
Levey, Allan I.
[J]. NEUROBIOLOGY OF AGING, 2012, 33 (01)
[9] Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population
Clarimon, J
Eerola, J
Hellström, I
Tienari, PJ
Singleton, A
[J]. NEUROSCIENCE LETTERS, 2004, 367 (02) : 168 - 170
[10] No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease
Sodeyama, N
Yamada, M
Itoh, Y
Suematsu, N
Matsushita, M
Otomo, E
Mizusawa, H
[J]. NEUROLOGY, 1999, 53 (05) : 1146 - 1148

← 1 2 3 4 5 →